Myriad Genetics - 26 Year Stock Price History | MYGN

Historical daily share price chart and data for Myriad Genetics since 1995 adjusted for splits. The latest closing stock price for Myriad Genetics as of September 24, 2021 is 33.31.
  • The all-time high Myriad Genetics stock closing price was 64.25 on November 06, 2000.
  • The Myriad Genetics 52-week high stock price is 36.95, which is 10.9% above the current share price.
  • The Myriad Genetics 52-week low stock price is 11.78, which is 64.6% below the current share price.
  • The average Myriad Genetics stock price for the last 52 weeks is 26.37.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Myriad Genetics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2021 30.1520 19.9200 36.6600 19.9200 33.3100 68.45%
2020 15.9993 27.3500 29.5300 9.7800 19.7750 -27.38%
2019 28.8167 29.0000 47.0800 20.9300 27.2300 -6.33%
2018 37.0251 34.9100 50.3400 27.2300 29.0700 -15.36%
2017 25.3318 16.9300 37.1400 15.4000 34.3450 106.03%
2016 28.9086 42.8300 42.8300 16.2600 16.6700 -61.38%
2015 36.9074 34.6100 46.1600 30.9400 43.1600 26.72%
2014 35.2888 21.7200 42.2100 21.0300 34.0600 62.35%
2013 27.1721 27.6800 34.2600 20.7900 20.9800 -23.01%
2012 25.3547 21.0000 30.6500 20.3600 27.2500 30.13%
2011 20.8191 22.2300 25.5300 17.8600 20.9400 -8.32%
2010 19.8918 26.6600 26.9200 14.4900 22.8400 -12.46%
2009 32.2280 34.1900 46.0000 22.8500 26.0900 -21.25%
2008 26.3477 23.0700 35.5150 17.3900 33.1300 42.74%
2007 20.5935 15.6750 29.4150 15.6150 23.2100 48.31%
2006 12.8096 10.8100 15.7750 10.5400 15.6500 50.48%
2005 9.6963 11.0600 12.9400 7.6000 10.4000 -7.60%
2004 8.3728 6.7900 11.9550 6.0950 11.2550 75.04%
2003 6.4308 7.5050 8.9600 4.3000 6.4300 -11.92%
2002 12.3661 25.1950 25.1950 6.6750 7.3000 -72.26%
2001 25.5927 34.7500 38.6250 12.9650 26.3200 -36.39%
2000 32.8078 11.4375 64.2500 10.3750 41.3750 259.78%
1999 3.6261 2.6575 11.7500 2.1563 11.5000 360.00%
1998 3.9467 6.0625 6.3125 1.8750 2.5000 -58.76%
1997 7.0036 6.0625 11.3450 5.4375 6.0625 -3.96%
1996 6.4582 7.3750 8.8125 4.3125 6.3125 -22.62%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.713B $0.639B
Myriad Genetics, Inc. is focused on revolutionizing patient care through the discovery, development and marketing of transformative molecular diagnostic tests that address pressing clinical needs across multiple medical specialties. Myriad is the pioneer and leader in molecular diagnostics, offering innovative products that transform patients' lives. These products include leading molecular diagnostic tests for hereditary cancer, urological cancer, lung cancer, autoimmune disorders and other diseases. Myriad has invested heavily in educating patients and healthcare professionals about the role genes and proteins play in disease. Myriad's hereditary cancer genetic testing, which helps healthcare professionals better manage and tailor medical care. Myriad is expanding their reach and increasing their impact on patient care by introducing new molecular diagnostic and companion diagnostic tests for a growing number of diseases.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71